Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00

Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00

The purpose of this study is to investigate visual outcomes and assess safety at 12 months (330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL.

This study will be conducted in regions where the test article is approved at the time of study start.

Inclusion Criteria:

• Diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision;
• Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures;
• Clear intraocular media other than cataract in both eyes;
• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Clinically significant corneal abnormalities including corneal dystrophy, inflammation or edema;
• Ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or color vision deficiencies;
• Glaucoma (uncontrolled or controlled with medication) or ocular hypertension;
• Pregnant or lactating;
• Expected to require ocular surgical or retinal laser treatment;
• Other protocol-specified exclusion criteria may apply.